Navigation Links
Radioimmunotherapy deemed safe and effective for lymphoma patients

Reston, Va. (July 10, 2013) A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies.

"Twelve years ago, when we started the study, it seemed that radioimmunotherapy could be a highly interesting tool that was both easy for clinicians to use and well-tolerated in patients. It also was clear that the use of iodine radionuclides was inconvenient for handling and not practical for patients because of the need for prolonged in hospital days due to radiation protection measures," said Andreas Lohri, MD, lead author of the study "Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas." "Although 90Y ibritumomab tiuxetanZevalinwas introduced shortly after we started the study, we felt it was important to do clinical experiments with other radionuclides."

The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma. All patients received an initial dose of 740 MBq/m2 body surface area of 177Lu-DOTA rituximab.. Doses were increased in steps of 185 MBq/m2 over a maximum of seven doses. Hematologic and nonhematologic toxicity was measured weekly up to week 10 or until recovery from the lowest level of blood cell count. Imaging with whole body computed tomography (CT) and 18F-FDG positron emission tomography (PET) or 18F-FDG PET/CT was conducted at baseline and at 8-12 weeks.

The maximum tolerated dose using 177Lu-DOTA rituximab was 1,665 MBq/m2. Toxicity was mainly hematologic, with thrombocytopenia and leukopenia noted as the dose-limiting toxicities, and nonhematologic toxicity was minor. Clinical responses occurred at all dose levels for patients with follicular (82 percent overall response rate) and mantle cell (21 percent response rate) lymphomas. With a median follow-up of almost seven years, the estimated median time of survival after radioimmunotherapy was four years.

"With 177Lu-DOTA Rituximab we can essentially do CD20 imaging," said Lohri. "At the moment, this may be academically interesting and could potentially be used in daily practice if compared to all forms of current PET imaging."


Contact: Susan Martonik
Society of Nuclear Medicine

Related medicine news :

1. Radioimmunotherapy could extend lives of advanced lymphoma patients
2. Talk Therapy Can Ease Depression, But No Single Type Deemed Best
3. Airports in N.Y., L.A., Hawaii Deemed Worst for Pandemic Spread
4. Study shows SBRT for stage I NSCLC safe and effective
5. New research finds flu shot effective regardless of circulating flu strain
6. Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
7. Long-term study reports deep brain stimulation effective for most common hereditary dystonia
8. Effective Environmental Services Launch New Websites to Serve Customers
9. Provant CEO, Heather Provino, Shares Key Insights on Employee Engagement & Effective Incentive Program Design at SHRM
10. Alta White Teeth Whitening System Now Available in New Package for Effective Results at Home
11. Animal thyroid extract as effective as T4 in treating hypothyroidism
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent ... bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to ... the patent-pending RECOVERY BRA for added comfort and support. The bra is easier ...
(Date:11/25/2015)... ... November 25, 2015 , ... Bcureful—a non-profit organization devoted to ... raising public awareness of the disorder while helping to bring expert medical care ... to bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... planning and monitoring. Their Care Plan software creates an agreement between the ... patient care plan, including financial, scheduling, monitoring, notification, and projections. Click ...
(Date:11/24/2015)... ... November 24, 2015 , ... Young patients with a ... Dr. Angela Wolfman and Dr. Kedar S. Lele, who are pediatric dentists in ... and fillings, the WaterLase iPlus 2.0™ system causes minimal discomfort and bleeding to the ...
(Date:11/24/2015)... ... November 25, 2015 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... upcoming Clinical Trial Supply East Asia Conference, to be held at the InterContinental ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015  Thanks to a donor with ... Mary,s Medical Center,s Sister Diane Grassilli Center for Women,s ... in San Francisco . ... stepped forward with a gift of $617,320 that allowed ... Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
(Date:11/24/2015)... and VANCOUVER, Nov. 24, 2015 /PRNewswire/ - ESSA ... EPIX ) announced today that the first patient ... of EPI-506 as a treatment for metastatic castration-resistant prostate ... and Canada.  --> the ... In the Phase 1/2 clinical trial, ESSA intends ...
Breaking Medicine Technology: